ArticleRSC advances2022
Homogeneous antibody-angiopep 2 conjugates for effective brain targeting.
Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Antibody-drug conjugates in breast cancer brain and leptomeningeal metastases: mechanistic insights and therapeutic progress.Cancer metastasis reviews · 2026Review
- A patent review of cyclin-dependent kinase 5 (CDK5) inhibitors (1999-2025).Frontiers in bioengineering and biotechnology · 2026Review
- Fc-Modified IVIG with Enhanced Blood-Brain Barrier Penetration Ameliorates Cognitive Deficits and Neuropathology in A53T α-Synuclein Transgenic Mice.Cellular and molecular neurobiology · 2025Article
- Development of blood-brain barrier-penetrating antibodies for neutralizing tick-borne encephalitis virus in the brain.mSphere · 2025Article
- A Site-Specific MiniAp4-Trastuzumab Conjugate Prevents Brain Metastasis.Molecular pharmaceutics · 2025Article
- Advancing through the blood-brain barrier: mechanisms, challenges and drug delivery strategies.ADMET & DMPK · 2025Review
- Discovery of a Novel Dual Targeting Peptide for Human Glioma: FromAdvanced pharmaceutical bulletin · 2024Article
- Review
- BrainBike peptidomimetic enables efficient transport of proteins across brain endothelium.RSC chemical biology · 2024Article
- Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours.Nature reviews. Clinical oncology · 2023Review
- Peptide Shuttles for Blood-Brain Barrier Drug Delivery.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Antibody-based therapy has shown great success in the treatment of many diseases, including cancers. While antibodies and antibody-drug conjugates (ADCs) have also been evaluated for central nervous system (CNS) disorders as well as brain tumors, their therapeutic efficacy can be substantially limited due to low permeability across the blood-brain barrier (BBB). Thus, improving BBB permeability of therapeutic antibodies is critical in establishing this drug class as a reliable clinical option for CNS diseases. Here, we report that, compared with a conventional heterogeneous conjugation, homogeneous conjugation of the synthetic BBB shuttle peptide angiopep-2 (Ang2) to a monoclonal antibody (mAb) provides improved binding affinity for brain microvascular endothelial cells
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.